Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Rosiglitazone/Metformin.

Keri Wellington1

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

Drugs
|July 22, 2005
PubMed
Summary
This summary is machine-generated.

Fixed-dose rosiglitazone/metformin combination therapy significantly improves glycemic control in type 2 diabetes patients. This combination therapy, including rosiglitazone (an insulin sensitizer) and metformin (reducing hepatic glucose output), offers a well-tolerated treatment option.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Drospirenone/ethinylestradiol 3mg/20microg (24/4 day regimen): a review of its use in contraception, premenstrual dysphoric disorder and moderate acne vulgaris.

Drugs·2007
Same author

Spotlight on bicalutamide 150mg in the treatment of locally advanced prostate cancer.

Drugs & aging·2007
Same author

Bicalutamide 150mg: a review of its use in the treatment of locally advanced prostate cancer.

Drugs·2006
Same author

Insulin glulisine.

Drugs·2006
Same author

Modified-release nifedipine: a review of the use of modified-release formulations in the treatment of hypertension and angina pectoris.

Drugs·2006
Same author

0.4% nitroglycerin ointment : in the treatment of chronic anal fissure pain.

Drugs·2006
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
Same journal

Linerixibat: First Approval.

Drugs·2026
See all related articles

Area of Science:

  • Endocrinology
  • Pharmacology
  • Metabolic Diseases

Background:

  • Type 2 diabetes mellitus (T2DM) management often requires combination therapy for effective glycemic control.
  • Rosiglitazone (thiazolidinedione) enhances insulin sensitivity, while metformin (biguanide) reduces hepatic glucose production.
  • A fixed-dose combination of rosiglitazone and metformin is available for T2DM patients inadequately controlled on metformin monotherapy.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of a fixed-dose combination of rosiglitazone and metformin in T2DM patients.
  • To compare the effectiveness of rosiglitazone/metformin combination therapy against metformin monotherapy and placebo.

Main Methods:

  • Bioequivalence of fixed-dose rosiglitazone/metformin with coadministration was confirmed in a pharmacokinetic study.

Related Experiment Videos

  • A 24-week randomized, double-blind study compared fixed-dose rosiglitazone/metformin (8 mg/2 g daily) with metformin (3 g daily).
  • Three 26-week randomized, double-blind, placebo-controlled studies assessed rosiglitazone plus metformin versus metformin alone.

    • Main Results:

    • Fixed-dose rosiglitazone/metformin significantly reduced glycosylated hemoglobin (HbA1c) and fasting plasma glucose (FPG) compared to metformin monotherapy.
    • Combination therapy with rosiglitazone and metformin demonstrated significantly greater reductions in HbA1c and FPG levels than metformin alone.
    • The fixed-dose combination was generally well tolerated, with a similar tolerability profile to metformin monotherapy.

    Conclusions:

    • Fixed-dose rosiglitazone/metformin provides a safe and effective antihyperglycemic treatment option for type 2 diabetes.
    • Combination therapy with rosiglitazone and metformin achieves superior glycemic control compared to metformin monotherapy.
    • The fixed-dose formulation offers a convenient and effective therapeutic strategy for managing T2DM.